Stocks › RYTM

RHYTHM PHARMACEUTICALS, INC.

RYTM·Nasdaq·United States United States·USD
$112.36
-4.44 (-3.80%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
RYTM
RHYTHM PHARMACEUTICALS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RYTMS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of RYTM by members of U.S. Congress · 0 on record

No congressional trades in RYTM on record.

Whale Activity

Position changes in RYTM reported for 2026-09-30 by 360 institutional filers
Increased: 128New: 52Held: 56Decreased: 80Closed: 26No prior filing: 18
  • Increased128
  • New52
  • Held56
  • Decreased80
  • Closed26
  • No prior filing18
FilerSharesValueChange
RA CAPITAL MANAGEMENT, L.P.6.7M$634.8Mheld
BlackRock, Inc.6.0M$568.9Mdecreased
BAKER BROS. ADVISORS LP5.6M$533.6Mheld
JPMORGAN CHASE & CO3.6M$340.8Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC3.1M$299.8Mincreased
PRIMECAP MANAGEMENT CO/CA/3.1M$291.8Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC3.0M$286.2Mdecreased
STATE STREET CORP2.6M$251.2Mincreased
PERCEPTIVE ADVISORS LLC2.5M$241.1Mdecreased
WESTFIELD CAPITAL MANAGEMENT CO LP2.5M$236.2Mincreased
PRICE T ROWE ASSOCIATES INC /MD/2.3M$222.3Mdecreased
GOLDMAN SACHS GROUP INC2.1M$201.6Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by RYTM insiders, by quarter · Form 4
-500.0K-250.0K0250.0K500.0K2025 Q1: -117.2K2025 Q12025 Q2: -193.8K2025 Q22025 Q3: -126.9K2025 Q32025 Q4: -56.6K2025 Q42026 Q1: -27.3K2026 Q12026 Q2: -41.6K2026 Q22026 Q3: -258.4K2026 Q32026 Q4: -55.9K2026 Q4

Recent Insider Transactions

607 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Shulman JosephChief Technical Officer Sale −45.9K $119.90 $5.5M Nov 18, 2026 Form 4 ↗
JEAN CHRISTOPHEDirector · Director Sale −5,000 $106.81 $534K Nov 17, 2026 Form 4 ↗
JEAN CHRISTOPHEDirector · Director Sale −2,500 $115.00 $288K Nov 17, 2026 Form 4 ↗
JEAN CHRISTOPHEDirector · Director Sale −2,500 $110.00 $275K Nov 17, 2026 Form 4 ↗
Meeker David PPresident and CEO · Director Sale −2,300 $105.19 $242K Sep 14, 2026 Form 4 ↗
Meeker David PPresident and CEO · Director Sale −1,817 $104.55 $190K Sep 14, 2026 Form 4 ↗
Meeker David PPresident and CEO · Director Sale −8,698 $103.43 $900K Sep 14, 2026 Form 4 ↗
Meeker David PPresident and CEO · Director Sale −30.7K $102.35 $3.1M Sep 14, 2026 Form 4 ↗
Meeker David PPresident and CEO · Director Sale −6,439 $101.75 $655K Sep 14, 2026 Form 4 ↗
Meeker David PPresident and CEO · Director Option exercise +50.0K $6.05 $303K Sep 14, 2026 Form 4 ↗
Smith Hunter CChief Financial Officer Sale −28.2K $106.20 $3.0M Aug 31, 2026 Form 4 ↗
Smith Hunter CChief Financial Officer Sale −11.5K $105.37 $1.2M Aug 31, 2026 Form 4 ↗
Smith Hunter CChief Financial Officer Sale −23.1K $104.59 $2.4M Aug 31, 2026 Form 4 ↗
Smith Hunter CChief Financial Officer Option exercise +57.2K $25.79 $1.5M Aug 31, 2026 Form 4 ↗
Shulman JosephChief Technical Officer Sale −5,079 $119.75 $608K Aug 13, 2026 Form 4 ↗
Shulman JosephChief Technical Officer Option exercise +2,024 $6.80 $14K Aug 13, 2026 Form 4 ↗
Garfield AlastairChief Scientific Officer Sale −800 $119.17 $95K Aug 13, 2026 Form 4 ↗
Garfield AlastairChief Scientific Officer Sale −3,400 $118.28 $402K Aug 13, 2026 Form 4 ↗
Garfield AlastairChief Scientific Officer Sale −1,556 $117.08 $182K Aug 13, 2026 Form 4 ↗
Garfield AlastairChief Scientific Officer Sale −2,007 $116.11 $233K Aug 13, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding RYTM · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
2.2M$241.7M0.01%Jun 30, 2026
PRIMECAP Odyssey Aggressive Growth Fund
PRIMECAP Odyssey Funds
2.0M$195.3M2.64%Jul 31, 2026
SMALLCAP World Fund Inc1.7M$189.6M0.20%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
1.6M$174.6M0.09%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
1.4M$157.3M0.19%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
1.2M$129.0M1.20%Jun 30, 2026
Federated Hermes Kaufmann Fund
Federated Hermes Equity Funds
1.0M$101.9M2.07%Jul 31, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
906.0K$100.6M0.21%Jun 30, 2026
PRIMECAP Odyssey Growth Fund
PRIMECAP Odyssey Funds
1.0M$100.1M1.65%Jul 31, 2026
T. Rowe Price New Horizons Fund, Inc.779.8K$86.6M0.59%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list RYTM's shares (CUSIP 76243J105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • JPMORGAN CHASE & CO.SCHEDULE 13G · passive (13G) · 3.6M shares5.1%
    Oct 13, 2026 · ↗
  • Perceptive Capital Solutions Holdings LPSCHEDULE 13G/A · passive (13G) · 729.2K shares1.1%
    May 15, 2026 · ↗
  • Perceptive Life Sciences Master Fund, Ltd.SCHEDULE 13G/A · passive (13G) · 2.8M shares4.1%
    May 15, 2026 · ↗
  • Joseph EdelmanSCHEDULE 13G/A · passive (13G) · 3.5M shares5.1%
    May 15, 2026 · ↗
  • Perceptive Advisors LLCSCHEDULE 13G/A · passive (13G) · 3.5M shares5.1%
    May 15, 2026 · ↗
  • GOLDMAN SACHS & CO. LLCSCHEDULE 13G/A · passive (13G) · 1.8M shares3.0%
    Feb 10, 2025 · ↗
  • THE GOLDMAN SACHS GROUP, INC.SCHEDULE 13G/A · passive (13G) · 1.8M shares3.0%
    Feb 10, 2025 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming RHYTHM PHARMACEUTICALS, INC. as client

No lobbying filings found naming RHYTHM PHARMACEUTICALS, INC. as the client.

Government Contracts

Federal awards to RHYTHM PHARMACEUTICALS, INC. · USAspending

No federal contract awards found for RHYTHM PHARMACEUTICALS, INC..

U.S. Patents

Recent USPTO applications naming RHYTHM PHARMACEUTICALS, INC.

No USPTO patent applications found for RHYTHM PHARMACEUTICALS, INC..

Annual Financials

From RYTM's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$189.8M$130.1M$77.4M$23.6M$3.2M
Operating income-$192.0M-$265.5M-$184.4M-$179.2M-$170.1M
Net income-$196.5M-$260.6M-$184.7M-$181.1M-$69.6M
Diluted EPS-$3.11-$4.34-$3.20-$3.47-$1.40
Operating cash flow-$115.7M-$113.9M-$136.2M-$173.4M-$146.0M
Cash and equivalents$54.3M$89.1M$60.1M$127.7M$59.2M
Total assets$480.2M$392.3M$332.7M$382.5M$329.5M
Total liabilities$210.2M$227.7M$163.0M$118.2M$45.4M
Shareholders' equity$139.1M$21.7M$169.8M$264.3M$284.2M

As RHYTHM PHARMACEUTICALS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in RYTM's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 3, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 7.01, 8.01, 9.01Results of operations · Reg FD disclosure · Other eventsAug 4, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 25, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsJun 15, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
    EDGAR ↗

About RHYTHM PHARMACEUTICALS, INC.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersBOSTON, MA
IncorporatedDE
Former namesRHYTHM METABOLIC, INC.